Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 2Phase 1/2 1

Status

Recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 3Gynecologic 1

Conditions

Ovarian Neoplasms 1Meningioma 1Glioma 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × TIC10 compound × 1 year × Clear all
NCT06012929 2026-01-26

A Study of ONC201 for Refractory Meningioma

University of Nebraska

Phase 2 Withdrawn
CNS

Meningioma

NCT05009992 2025-12-17

PNOC022

University of California, San Francisco

Phase 2 Recruiting
360 enrolled
CNS

Diffuse Intrinsic Pontine Glioma

NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Jazz Pharmaceuticals

Phase 2 Terminated
73 enrolled 13 charts 1 FDA
CNS

Glioma

NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
62 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡